Thomas Rose, PhD, is Head of Expression Systems at ProBioGen. He received his MSc in Biotechnology from the University of Applied Science in Berlin, his PhD in Biochemistry from the Free University of Berlin and joined ProBioGen in 2001. His work focuses on cell line development and expression technologies for protein drugs. He was instrumental in establishing the Freedom™ CHO-S™ Kit, as well as ProBioGen’s CHO.RiGHT® platform, Pathway Modulator and DirectedLuck® technologies. He also has extensive experience in cell line development for a variety of complex proteins.
Transposases have eased cell line development. Taking this concept to a new level, we equipped our hyperactive transposase with epigenetic readers that targets highly active genomic sites in the host cell line and designed advanced transposons with optimized ITRs for most efficient and clean integration. DirectedLuck® delivers highly productive clones and bulk pools ready for manufacturing and is particularly suited for heterodimeric formats, polyclonal antibody cell lines and viral vector packaging cell lines.